Whereas there are not any Covid-19 vaccines accredited but and trials are nonetheless beneath solution to show they’re protected and efficient, main drugmakers have been funded to start manufacturing early to expedite deliveries, because the pandemic has killed greater than 1.2 million individuals worldwide.
AstraZeneca stated final week that it was holding again deliveries of its Covid-19 vaccine candidate whereas it awaits the info from late-stage scientific trials, which obtained delayed on account of a summer time dip in UK coronavirus infections.
Serum declined to touch upon whether or not the 40 million doses of the AstraZeneca vaccine have been meant for world provide or just for India.
For manufacturing of the Novavax vaccine, Serum stated it has acquired the majority of the vaccine from the US firm and can quickly fill and end them in vials.
Coronavirus live updates
Novavax, which is testing its vaccine in a late stage study in the UK, last month postponed the start of its US trial by roughly a month due to delays in scaling up the manufacturing process.
Serum said it had enrolled 1,600 participants in India for the late-stage trials of AstraZeneca’s candidate, and also plans to seek regulatory approval to run late-stage trials for the Novavax vaccine.
The AstraZeneca vaccine, co-developed by Oxford University, is the most advanced in human testing in India, Serum said, adding that the company and the Indian Council of Medical Research (ICMR) will pursue “early availability” of the shot in India.
The ICMR, a federal government body, had funded the clinical trial site fees for the AstraZeneca vaccine, Serum said. The company and the ICMR are currently conducting Phase 2/3 clinical trials of the shot at 15 centres across India.
The news came as coronavirus infections in India, the world’s second-worst hit country, reached 8.68 million on Thursday and the death toll increased to more than 128,000.
India also has at least two home-grown Covid-19 vaccine candidates in development, while local drugmaker Dr Reddy’s Labs is carrying out a trial in the country for Russia’s vaccine candidate.
Earlier this week, Pfizer and its partner BioNTech said their vaccine candidate had proven more than 90% effective based on initial trial results. Pfizer said it was committed to advancing its engagement with India’s government to supply its potential vaccine in the country.